CURE Pharmaceuticals, developer of drug delivery technology and pharmaceutical cannabinoid molecules, has signed a memorandum of understanding (MOU), entering into a research collaboration with two Israeli companies.
Research collaboration
The collaboration with Therapix Biosciences (speciality clinical-stage pharma company) and Assuta Medical Center (private medical service centre based in Israel) will target openings in the traditional pharmaceutical market where there are currently unmet needs that could be served by cannabinoid-based options.
“CURE is the ideal partner for us to enter this promising field of cutting-edge personalised cannabinoid-based therapeutics. This deal has all the signs of a fruitful venture,” asserted Dr Ascher Scmulewitz, Therapix chairman.
Under the terms of the MOU, the companies will formalise the pooling of professional, scientific, financial resources and expertise to benefit from each of its respective advantages and capabilities to develop new therapeutic products in the fields of personalised medicine and cannabinoids.
More specifically, in partnership with CURE, Therapix will provide support and expertise in the development of pharmaceutical products, while Assuta will support the early research and development of potential projects through its research and facilities.
“Assuta is happy to enter into this collaboration with CURE and Therapix and are confident that the parties cooperation will be a successful one, with many other projects to follow,” said Professor Ari Shamiss, CEO, Assuta Medical Center.